ksn.com

EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet

TARRYTOWN, N.Y., March 08, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced The Lancet published one-year results from the pivotal PULSAR and PHOTON trials for ...
Insurancenewsnet.com

EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...
Yahoo Finance

Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Healthline

Eylea and Eylea HD Dosing

Eylea and Eylea HD are prescription medications used to treat various eye conditions. The dosage and frequency of injections of these drugs vary based on the specific condition and the form of the ...
streetinsider

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

TARRYTOWN, N.Y., Feb. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive results from the Phase 3 QUASAR trial investigating ...
ad-hoc-news

The EYLEA Injection. Regeneron’s VEGF blocker anchors a key eye therapy line

EYLEA Injection sits in a stainless steel tray under a bright exam lamp, its small glass vial held between a nurse’s gloved fingers as she double-checks the label before a retina specialist steps in.
streetinsider

Regeneron (REGN) Reports Three-year Results for EYLEA HD Injection 8 mg

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive three-year (156-week) data for EYLEA HD ® (aflibercept) Injection 8 mg from an extension study of the Phase 3 PHOTON trial in ...